NEW YORK (Reuters) - Momenta Pharmaceuticals Inc said on Friday U.S. regulators had accepted for review its generic version of Teva Pharmaceutical Industries Ltd's multiple sclerosis drug Copaxone, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback